Name:
Yuritmic. Release form Tablets. Dosage 5 mg, 10 mg. Packing: 30 or 60 pcs.
Description:
: Tablets, film-coated, yellow, round, scored, divided into 4 parts, embossed “BIS5” or “BIS10” on one side. MMHBisoprolol. Composition 1 tab. bisoprolol (in the form of fumarate) 5 mg Excipients: anhydrous calcium hydrogen phosphate, microcrystalline cellulose, pregelatinized corn starch, sodium croscarmellose, anhydrous colloidal silicon dioxide, magnesium stearate. Film shell: lactose monohydrate, hydroxypropyl methylcellulose, titanium dioxide (E171), macrogol 4000, yellow iron oxide (E172) 15 pcs. – blisters (2) – packs of cardboard. 15 pcs. – blisters (4) – packs of cardboard. The drug is approved for use as an over-the-counter tablet., Cover. shell 10 mg: 30 or 60 pcs. Reg. №: 10844/20 dated 08/27/2020 – Active Tablets, film-coated, light orange, round, notched, divisible into 4 parts, embossed “BIS10” on one side. 1 tab. bisoprolol (in the form of fumarate) 10 mg Excipients: anhydrous calcium hydrogen phosphate, microcrystalline cellulose, pregelatinized corn starch, sodium croscarmellose, anhydrous colloidal silicon dioxide, magnesium stearate. Film shell: lactose monohydrate, hydroxypropyl methylcellulose, titanium dioxide (E171), macrogol 4000, iron oxide yellow (E172), iron oxide red (172). 15 pcs. – blisters (2) – packs of cardboard. 15 pcs. – blisters (4) – packs of cardboard. Pharmacological action Selective beta1-blocker Indications for use Arterial hypertension, prevention of angina attacks, chronic heart failure. Dosing regimenIndividual. For oral administration, the daily dose is 2.5-10 mg, the frequency of administration is 1 time / day. The maximum daily dose is 10 mg. Side effects From the side of the nervous system: weakness, fatigue, dizziness, headache, sleep disorders, mental disorders (depression, rarely – hallucinations), a feeling of cold and paresthesia in the extremities. From the side of the cardiovascular system: orthostatic hypotension, bradycardia, impaired AV conduction, the appearance of symptoms of heart failure, aggravation of intermittent claudication and the main clinical symptoms in Raynaud’s syndrome. On the part of the organ of vision: a decrease in the secretion of lacrimal fluid, conjunctivitis. From the digestive system: diarrhea, constipation, nausea, abdominal pain. From the musculoskeletal system: muscle weakness, muscle cramps. From the skin and subcutaneous tissues: skin itching; in some cases – increased manifestations of psoriasis, the appearance of psoriasis-like rashes. From the respiratory system: in predisposed patients, symptoms of bronchial obstruction may appear. Others: sweating, hot flashes, impaired potency, reduced glucose tolerance in patients with diabetes mellitus, allergic reactions. Contraindications for use Acute heart failure, chronic heart failure in the stage of decompensation, cardiogenic shock, collapse, II and III degree AV blockade (without a pacemaker), SSS; sinoatrial blockade, severe bradycardia (heart rate <50 beats/min), Prinzmetal's angina, marked decrease in blood pressure (systolic blood pressure <90 mm Hg), history of severe forms of bronchial asthma and COPD, late stages of peripheral circulatory disorders, Raynaud's disease , pheochromocytoma (without the simultaneous use of alpha-blockers), metabolic acidosis, simultaneous use of MAO inhibitors (with the exception of type B MAO inhibitors), children and adolescents under 18 years of age, hypersensitivity to bisoprolol and other beta-blockers. Use during pregnancy and lactation Use during pregnancy and lactation is not recommended and is possible when the expected benefit to the mother outweighs the potential risk of side effects in the fetus and child. In exceptional cases of use during pregnancy, bisoprolol should be discontinued 72 hours before the expected date of delivery due to the possibility of bradycardia, arterial hypotension, hypoglycemia and respiratory depression in the newborn. If cancellation is not possible, then it is necessary to carefully monitor the condition of the newborn within 72 hours after delivery. If it is necessary to use bisoprolol during lactation, breastfeeding should be stopped. Application for violations of liver function Do not exceed a dose of 10 mg / day for severe violations of liver function. Application for violations of renal function Do not exceed a dose of 10 mg / day in renal failure (CC less than 20 ml / min). Use in children Not recommended for use in children. Use with caution in psoriasis and with indications of psoriasis in a family history, diabetes mellitus in the decompensation phase, with a predisposition to allergic reactions. With pheochromocytoma, the use of bisoprolol is possible only after taking alpha-blockers. To prevent sudden withdrawal of bisoprolol, the course of treatment should be completed slowly with a gradual decrease in dose. Before surgery, the anesthesiologist should be informed about the treatment with bisoprolol. Bisoprolol at a dose of more than 10 mg / day should be used only in exceptional cases. This dose should not be exceeded in case of renal insufficiency (CC less than 20 ml / min) and severe liver dysfunction. Avoid drinking alcohol during treatment. Influence on the ability to drive vehicles and control mechanisms Use with caution in patients whose activities are associated with the need for concentration and high speed of psychomotor reactions. Drug Interactions With the simultaneous use of antacids and antidiarrheals, a decrease in the absorption of beta-blockers is possible. With the simultaneous use of antiarrhythmic drugs, a sharp decrease in blood pressure, a decrease in heart rate, the development of arrhythmias and / or heart failure are possible. With the simultaneous use of antihypertensive agents, an increase in the antihypertensive effect is possible. With the simultaneous use of cardiac glycosides, conduction disturbances are possible. With the simultaneous use of sympathomimetics (including those included in cough drops, nasal drops, eye drops), the effectiveness of bisoprolol decreases. With the simultaneous use of verapamil, diltiazem, a sharp decrease in blood pressure, a decrease in heart rate, the development of arrhythmias and / or heart failure are possible. With the simultaneous use of guanfacine, severe bradycardia and conduction disturbances are possible. With the simultaneous use of insulin, oral hypoglycemic agents, the effect of insulin or other hypoglycemic agents is enhanced (regular monitoring of plasma glucose levels is necessary). With the simultaneous use of clonidine, severe bradycardia, arterial hypotension, and conduction disturbances are possible. In the event of a sudden withdrawal of clonidine in patients receiving bisoprolol, a sharp increase in blood pressure is possible. With the simultaneous use of nifedipine, other calcium channel blockers, dihydropyridine derivatives, the antihypertensive effect of bisoprolol is enhanced. With the simultaneous use of reserpine, alpha-methyldopa, severe bradycardia is possible. With the simultaneous use of rifampicin, a slight decrease in T1 / 2 of bisoprolol is possible. With the simultaneous use of ergotamine derivatives (including drugs for the treatment of migraine containing ergotamine), the symptoms of peripheral circulatory disorders increase. Holiday conditions Without a prescription. Buy Yuritmik tablets p/o 10mg №15x2 Price for Yuritmik tablets p/o 10mg №15x2
INN | BISOPROLOL |
---|---|
The code | 142 235 |
Barcode | 5 907 626 709 421 |
Dosage | 10mg |
Active substance | bisoprolol |
Manufacturer | Lek S.A., Slovenia |
Importer | LLC "NOVA-PHARM", Republic of Belarus, 223028, Minsk region, Minsk district, Zhdanovichsky s / s, ag. Zhdanovichi, Zvezdnaya st., 19A, room 101; Trade and production republican unitary enterprise "BELPHARMATSIYA", 220005, Belarus, Minsk, st. V. Khoruzhey, 11; Closed joint-stock company "UNIPHARM", 223060, Minsk region, Novodvorsky s / council, 40-1, room. 36, area of the village of Bolshoye Stiklevo; Additional Liability Company "Farmin", 220125 Minsk, Independence Avenue, 177, room 62; Limited Liability Company "COMFARM", 220131 Minsk, Sosnovy Bor st., 4, office 1; Limited Liability Company "ISKAMED", 220036, Minsk, K.Libknekhta st., 70, office 6; Additional Liability Company "TISHAS", 220028 Belarus, Minsk, Mayakovsky st., 144, room 7; Limited Liability Company "VitPharmMarket", 210004 Vitebsk, 5th Cooperative St., 8; IOOO "Interfarmaks", Republic of Belarus, 223028, Minsk region, Minsk district, Zhdanovichsky s / s, ag. Zhdanovichi, st. Zvezdnaya, 19A-5, pom. 5-2; IOOO "Interfarmaks", Republic of Belarus, 223028, Minsk region, Minsk district, Zhdanovichsky s / s, ag. Zhdanovichi, st. Zvezdnaya, 19A-5, pom. 5-2; Limited Liability Company "VitPharmMarket", 210004 Vitebsk, 5th Cooperative St., 8; Limited Liability Company "ISKAMED", 220036, Minsk, K.Libknekhta st., 70, office 6; [x] Closed joint-stock company "UNIPHARM", 223060, Minsk region, Novodvorsky s / council, 40-1, room. 36, area of the village of Bolshoye Stiklevo; [x] Additional Liability Company "TISHAS", 220028 Belarus, Minsk, Mayakovskogo st., 144, room 7; [x] Additional Liability Company "Farmin", 220125 Minsk, Nezalezhnosti Avenue, 177, room 62; [x] LLC "NOVA-PHARM", Republic of Belarus, 223028, Minsk region, Minsk district, Zhdanovichsky s / s, ag. Zhdanovichi, Zvezdnaya st., 19A, room 101; [x] Trade and production republican unitary enterprise "BELPHARMATSIYA", 220005, Belarus, Minsk, st. V. Khoruzhey, 11; [x] Limited Liability Company "COMFARM", 220131 Minsk, Sosnovy Bor st., 4, office 1 |
Reviews
There are no reviews yet.